HVTN 702

Status:Ongoing
Phase:III, IIb
Principal Investigator(s):Glenda Gray, MBBCH, FCPaed (SA)
Objective:This study will evaluate the preventive vaccine efficacy, safety, and tolerability of ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59 in HIV-seronegative South African adults over 24 months and potentially up to 36 months from enrollment.   *Vaccinations have stopped early due to non-efficacy but participants are still being followed   Last updated Aug 25, 2021
Prevention Option(s):HIV Vaccine
Study Design:Double-blind, Randomized
Arms and Assigned Interventions
DescriptionActive Comparator: ALVAC-HIV + subtype C gp120/MF59 2700 participants will receive an IM injection of ALVAC-HIV (vCP2438) at months 0 and 1, and an IM injection of ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59 at months 3, 6, and 12.
Mode of DeliveryIntramuscular
ARMsExperimental
Results: Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults
Official Code: NCT02968849
Related Publications:
Experimental HIV Vaccine Regimen Ineffective in Preventing HIV
Trial Sponsors: Bill & Melinda Gates Foundation, GSK, NIAID, Sanofi Pasteur
Start Date
End Date
October 26, 2016
September 1, 2021
Enrollment:5,407
Age range: 18 Years ↔ 35 Years
Population:Cisgender Men, Cisgender Women